Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Sang Taek Kim"'
Autor:
Sang Taek Kim, Yumin Hong
Publikováno v:
Journal of Industrial Economics and Business. 33:79-102
Autor:
Rim Ouni, Ying Henderson, Yunyun Chen, Naimah Turner, William Padron, Ali Dadbin, Elena McBeath Fujiwara, Jennifer R. Wang, Maria Cabanillas, Romana Dadu, Marie-Claude Hofmann, Mark E. Zafereo, Sang Taek Kim, Stephen Lai, Roza Nurieva
Publikováno v:
Leading Edge of Cancer Research Symposium: Poster Session.
Autor:
Sang Taek Kim, Sung Soo Ahn, Jason Jungsik Song, Yong Beom Park, Seung Min Jung, Mindong Sung, Sang Won Lee, Minkyung Kwon
Publikováno v:
Clinical Lung Cancer. 20:e299-e308
Lung cancer is one of the most lethal malignancies, with a 5-year survival rate 20% in patients with stage IV lung cancer. Impaired host immunity is associated with lung cancer pathogenesis, and interferon gamma (IFN-γ) plays an important role in an
Autor:
Van Anh Trinh, Daniel H. Johnson, Michael A. Davies, Dai Ogata, P. Hwu, Yinghong Wang, Cara Haymaker, Alexander J. Lazar, Yared Hailemichael, Jared K. Burks, Roza Nurieva, Hamzah Abu-Sbeih, Mario L. Marques-Piubelli, Luisa M. Solis, Chrystia M. Zobniw, Salah Eddine Bentebibel, Adi Diab, Alejandro Francisco Cruz, Suhendan Ekmekcioglu, Chantal M. Saberian, Brenda Denisse Melendez, Noha Abdel-Wahab, Christine A. Spillson, Gregory A. Lizee, Khalida M. Wani, Cassian Yee, Wei Lu, Jonathan L. Curry, May Daher, Sang Taek Kim Md, Wai Chin Foo, Jennifer A. Wargo
Publikováno v:
SSRN Electronic Journal.
Immune checkpoint blockade (ICB) for cancer is associated with high response rates but also high rates of adverse events. To elucidate the underlying immunobiology, we profiled gene expression in intestinal, colitis, and tumor tissue from ICB-treated
Autor:
Begoña Lainez, Vincent P. Schulz, Eric D. Baum, Patrick G. Gallagher, Sang Taek Kim, Jin-Young Choi, Joe Craft, Jennifer Setlur, David E. Karas
Publikováno v:
The Journal of Immunology. 201:1359-1372
Follicular helper T (Tfh) cells are necessary for germinal center B cell maturation during primary immune responses; however, the T cells that promote humoral recall responses via memory B cells are less well defined. In this article, we characterize
Autor:
Maria E. Suarez-Almazor, Sang Taek Kim
Publikováno v:
Expert Review of Clinical Immunology. 15:211-213
By targeting inhibitory checkpoint molecules, with resultant reinvigoration of antitumor immunity, immune checkpoint inhibitors (ICIs) have opened a new chapter in cancer treatment [1]. Full activa...
Autor:
Daniel H. Johnson, Jean Tayar, Adi Diab, Maria E. Suarez-Almazor, Patrick Hwu, Sang Taek Kim, Marc Uemura, Salvador Garcia, Van Anh Trinh
Publikováno v:
Annals of the Rheumatic Diseases. 76:2061-2064
BackgroundImmune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with numerous cancers. However, these therapies are associated with immune-related adverse events (irAEs), which are inflammatory side effects potentially
Autor:
Octavian Henegariu, Allison Ehrlich, Peiying Shan, Wai Ho Tang, Alfred L. M. Bothwell, Jae Hun Shin, Wook-Jin Chae, Diane McMahon-Pratt, Alexandra M. Teixeira, Sang Taek Kim, John Hwa, Jong Hyun Park, Pamela Y. Chan, Liming Hao, Karen Goldsmith-Pestana, Diane S. Krause, Patty J. Lee, Stephen E. Maher, Carla V. Rothlin
Publikováno v:
Immunity. 44:246-258
Exposure to a plethora of environmental challenges commonly triggers pathological type 2 cell-mediated inflammation. Here we report the pathological role of the Wnt antagonist Dickkopf-1 (Dkk-1) upon allergen challenge or non-healing parasitic infect
Autor:
Eduardo Ferreira Borba, Joe Craft, Célio Roberto Gonçalves, Solange Carrasco, Sandra Gofinet Pasoto, Priscila Rezende da Costa, Sang Taek Kim, John Hsi En Ho, Jin-Young Choi, Esper G. Kallas, Viviane Bunin, Eloisa Bonfa
Publikováno v:
Arthritis & Rheumatology. 67:988-999
Objective To assess circulating follicular helper-like CD4+ T (cTfh-like) cells in systemic lupus erythematosus (SLE) and determine their relationship to disease activity.
Publikováno v:
Poster Presentations.
Background Immune checkpoint inhibitors (CPIs) have significantly improved outcomes for patients with various cancers. However, CPIs are associated with immune-related adverse events (irAEs). Two to three percent of patients receiving a CPI develop a